Four High-Growth GARP Stocks for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 26 2026
0mins
Source: NASDAQ.COM
- DaVita's Growth Potential: DaVita, a leading provider of dialysis services in the U.S., demonstrated strong momentum in Q1 2026 with an impressive long-term growth rate of 20.2%, making it an ideal GARP investment choice due to its reasonable PEG and P/E ratios, showcasing sustainable profitability.
- Integra's Market Demand: Integra LifeSciences leads in regenerative medicine, with a projected five-year growth rate of 5.9% for 2026, as steady demand in neurosurgery and ENT products highlights the company's strong competitive position in the medical device market.
- Braskem's Industry Position: Braskem manufactures petrochemical products in Brazil and internationally, with an expected long-term growth rate of 16.8%, and its superior value and growth scores make it stand out in GARP investment strategies, reflecting robust performance in the global market.
- LyondellBasell's Historical Growth: LyondellBasell holds a significant position in the global plastics and chemicals industry, boasting a historical growth rate of 49.4%, and its reasonable PEG and P/E ratios position it as a preferred choice for GARP investors, demonstrating strong market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to fall
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 230.720
Low
144.00
Averages
162.50
High
190.00
Current: 230.720
Low
144.00
Averages
162.50
High
190.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company's robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company's international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company's U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Buffett Retires, Abel Takes Over as CEO of Berkshire Hathaway
- Succession Announcement: Warren Buffett has announced his retirement and appointed Greg Abel as the new CEO of Berkshire Hathaway; while Abel takes the helm, Ted Weschler continues to manage portions of the investment portfolio, indicating continuity in corporate governance.
- Strong Investment Performance: Stocks personally selected by Weschler, DaVita and SiriusXM, have surged over 102% and 50% year-to-date in 2026, respectively, reflecting his investment acumen and market recognition, which bolsters long-term confidence in Berkshire's investment strategy.
- Investment Strategy Continuity: Although Abel may introduce some changes in investment decisions, Berkshire continues to adhere to traditional value investing principles by holding stocks like DaVita and SiriusXM, demonstrating a commitment to successful investment models during this transition.
- Shift Towards Technology Investments: Under Abel's leadership, Berkshire's participation in a $10 billion private placement of Alphabet shares indicates a growing interest in tech stocks, yet the company has not completely abandoned traditional value stocks, ensuring diversity and stability in its investment portfolio.
See More
Berkshire Hathaway's Investment Strategy Post-Buffett Retirement
- Continuity in Investment Decisions: Although Greg Abel has taken over as CEO, Ted Weschler remains a key player in Berkshire Hathaway's investment decisions, indicating that the company continues to uphold Buffett's traditional investment philosophy post-retirement.
- Strong Stock Performance: Weschler's selections, DaVita and SiriusXM, have performed exceptionally well in 2026, with DaVita's shares up over 102% and SiriusXM's up over 50%, showcasing the potential returns from the company's investments in healthcare and media sectors.
- Portfolio Adjustments: Berkshire's exit from positions in stocks like Mastercard and UnitedHealth Group in the first quarter suggests that Abel is adopting a more proactive adjustment strategy in portfolio management, which could influence future investment directions.
- Increased Tech Stock Participation: Since taking over, Abel has intensified investments in technology stocks, as evidenced by Berkshire's $10 billion private placement in Alphabet, demonstrating a gradual expansion into emerging tech sectors while maintaining traditional value investing principles.
See More
Buffett Retires, Abel Succeeds as CEO of Berkshire Hathaway
- Succession Appointment: Following Buffett's retirement, Abel has been appointed as CEO of Berkshire Hathaway, and while he is the new captain, the management of the investment portfolio remains under Weschler, indicating stability during leadership transition.
- Strong Investment Performance: Stocks personally selected by Weschler, such as DaVita and SiriusXM, have performed exceptionally well in 2026, with DaVita's share price up over 102% year-to-date and SiriusXM up over 50%, reflecting the company's success in value investing.
- Investment Strategy Continuity: Although Abel holds greater authority in investment decisions, Berkshire continues to adhere to traditional value investing strategies, with Weschler's ongoing management suggesting that the company will not completely deviate from its historically successful investment philosophy.
- Increased Tech Stock Participation: Since taking over, Abel has intensified investments in technology stocks, as evidenced by Berkshire's participation in a $10 billion private placement of Alphabet shares, demonstrating the company's gradual adaptation to market changes while maintaining traditional investment principles.
See More
DaVita HealthCare Stock Shows Strong Performance
- Stock Performance: DaVita HealthCare (DVA) closed at $213.04, up 1% from the previous session, outperforming the S&P 500's 0.1% decline, indicating its relative strength in the market.
- Monthly Gains: The stock has risen 7.85% over the past month, significantly surpassing the Medical sector's 1.97% gain and the S&P 500's 1.34% loss, highlighting the company's competitive edge.
- Positive Earnings Outlook: The upcoming earnings report is projected to show an EPS of $4.01, a 35.93% increase year-over-year, with net sales expected at $3.53 billion, up 4.53%, which will further bolster investor confidence.
- Strong Analyst Ratings: DaVita currently holds a Zacks Rank of #1 (Strong Buy), reflecting analysts' confidence in its future performance, with #1 rated stocks averaging a 25% annual return since 1988, showcasing its investment potential.
See More
Four Stocks Near 52-Week Highs with Growth Potential
- Murphy USA Growth Momentum: Murphy USA's first-quarter fuel contribution strengthened to $0.35 per gallon, with merchandise contribution rising by 7.3%, and management plans to open 45 to 55 new stores in 2026, indicating strong market expansion intentions.
- DaVita Performance Boost: DaVita raised its full-year adjusted operating income guidance to $2.15 to $2.25 billion, with first-quarter revenues reaching $3.42 billion, showcasing robust growth across its 3,262 centers worldwide.
- Hewlett Packard Business Expansion: Hewlett Packard expanded its ProLiant edge portfolio for AI and mission-critical workloads, achieving record revenues in the second quarter, prompting management to raise full-year revenue and EPS guidance, reflecting strong market demand.
- Vishay Operational Momentum: Vishay's first-quarter revenues reached $839.2 million with gross margin expanding to 21%, and management guided second-quarter revenues to $875 to $905 million, indicating sustained market demand and product innovation.
See More
Investment Comparison: DaVita vs. Encompass Health
- Market Share and Revenue: DaVita operates over 3,200 dialysis centers globally, serving approximately 295,000 patients, with FY 2025 revenue nearing $13.6 billion, reflecting a 6.5% year-over-year growth that underscores its strong market position in kidney care.
- Profitability and Risks: Despite DaVita's net income of $746.8 million and a net margin of about 5.5%, its heavy reliance on government reimbursements (accounting for 68% of U.S. dialysis patient service revenue) adds significant business risk, particularly in light of potential policy shifts.
- Expansion and Growth: Encompass Health operates 173 inpatient rehabilitation hospitals across the U.S., generating approximately $5.9 billion in revenue for FY 2025, marking a 10.5% growth, which indicates robust expansion and improved profitability in the post-acute care market.
- Financial Health and Investment Potential: Encompass Health's net income reached nearly $566.2 million with a net margin of 9.5%, and its lower debt-to-equity ratio (around 1.1x) along with free cash flow of approximately $439.2 million provides ample funding for future expansion, showcasing its strong financial health.
See More
Buffett Retires, Abel Takes Over as CEO of Berkshire Hathaway
- Succession Announcement: Warren Buffett has announced his retirement and appointed Greg Abel as the new CEO of Berkshire Hathaway; while Abel takes the helm, Ted Weschler continues to manage portions of the investment portfolio, indicating continuity in corporate governance.
- Strong Investment Performance: Stocks personally selected by Weschler, DaVita and SiriusXM, have surged over 102% and 50% year-to-date in 2026, respectively, reflecting his investment acumen and market recognition, which bolsters long-term confidence in Berkshire's investment strategy.
- Investment Strategy Continuity: Although Abel may introduce some changes in investment decisions, Berkshire continues to adhere to traditional value investing principles by holding stocks like DaVita and SiriusXM, demonstrating a commitment to successful investment models during this transition.
- Shift Towards Technology Investments: Under Abel's leadership, Berkshire's participation in a $10 billion private placement of Alphabet shares indicates a growing interest in tech stocks, yet the company has not completely abandoned traditional value stocks, ensuring diversity and stability in its investment portfolio.
See More
Berkshire Hathaway's Investment Strategy Post-Buffett Retirement
- Continuity in Investment Decisions: Although Greg Abel has taken over as CEO, Ted Weschler remains a key player in Berkshire Hathaway's investment decisions, indicating that the company continues to uphold Buffett's traditional investment philosophy post-retirement.
- Strong Stock Performance: Weschler's selections, DaVita and SiriusXM, have performed exceptionally well in 2026, with DaVita's shares up over 102% and SiriusXM's up over 50%, showcasing the potential returns from the company's investments in healthcare and media sectors.
- Portfolio Adjustments: Berkshire's exit from positions in stocks like Mastercard and UnitedHealth Group in the first quarter suggests that Abel is adopting a more proactive adjustment strategy in portfolio management, which could influence future investment directions.
- Increased Tech Stock Participation: Since taking over, Abel has intensified investments in technology stocks, as evidenced by Berkshire's $10 billion private placement in Alphabet, demonstrating a gradual expansion into emerging tech sectors while maintaining traditional value investing principles.
See More
Buffett Retires, Abel Succeeds as CEO of Berkshire Hathaway
- Succession Appointment: Following Buffett's retirement, Abel has been appointed as CEO of Berkshire Hathaway, and while he is the new captain, the management of the investment portfolio remains under Weschler, indicating stability during leadership transition.
- Strong Investment Performance: Stocks personally selected by Weschler, such as DaVita and SiriusXM, have performed exceptionally well in 2026, with DaVita's share price up over 102% year-to-date and SiriusXM up over 50%, reflecting the company's success in value investing.
- Investment Strategy Continuity: Although Abel holds greater authority in investment decisions, Berkshire continues to adhere to traditional value investing strategies, with Weschler's ongoing management suggesting that the company will not completely deviate from its historically successful investment philosophy.
- Increased Tech Stock Participation: Since taking over, Abel has intensified investments in technology stocks, as evidenced by Berkshire's participation in a $10 billion private placement of Alphabet shares, demonstrating the company's gradual adaptation to market changes while maintaining traditional investment principles.
See More
DaVita HealthCare Stock Shows Strong Performance
- Stock Performance: DaVita HealthCare (DVA) closed at $213.04, up 1% from the previous session, outperforming the S&P 500's 0.1% decline, indicating its relative strength in the market.
- Monthly Gains: The stock has risen 7.85% over the past month, significantly surpassing the Medical sector's 1.97% gain and the S&P 500's 1.34% loss, highlighting the company's competitive edge.
- Positive Earnings Outlook: The upcoming earnings report is projected to show an EPS of $4.01, a 35.93% increase year-over-year, with net sales expected at $3.53 billion, up 4.53%, which will further bolster investor confidence.
- Strong Analyst Ratings: DaVita currently holds a Zacks Rank of #1 (Strong Buy), reflecting analysts' confidence in its future performance, with #1 rated stocks averaging a 25% annual return since 1988, showcasing its investment potential.
See More
Four Stocks Near 52-Week Highs with Growth Potential
- Murphy USA Growth Momentum: Murphy USA's first-quarter fuel contribution strengthened to $0.35 per gallon, with merchandise contribution rising by 7.3%, and management plans to open 45 to 55 new stores in 2026, indicating strong market expansion intentions.
- DaVita Performance Boost: DaVita raised its full-year adjusted operating income guidance to $2.15 to $2.25 billion, with first-quarter revenues reaching $3.42 billion, showcasing robust growth across its 3,262 centers worldwide.
- Hewlett Packard Business Expansion: Hewlett Packard expanded its ProLiant edge portfolio for AI and mission-critical workloads, achieving record revenues in the second quarter, prompting management to raise full-year revenue and EPS guidance, reflecting strong market demand.
- Vishay Operational Momentum: Vishay's first-quarter revenues reached $839.2 million with gross margin expanding to 21%, and management guided second-quarter revenues to $875 to $905 million, indicating sustained market demand and product innovation.
See More
Investment Comparison: DaVita vs. Encompass Health
- Market Share and Revenue: DaVita operates over 3,200 dialysis centers globally, serving approximately 295,000 patients, with FY 2025 revenue nearing $13.6 billion, reflecting a 6.5% year-over-year growth that underscores its strong market position in kidney care.
- Profitability and Risks: Despite DaVita's net income of $746.8 million and a net margin of about 5.5%, its heavy reliance on government reimbursements (accounting for 68% of U.S. dialysis patient service revenue) adds significant business risk, particularly in light of potential policy shifts.
- Expansion and Growth: Encompass Health operates 173 inpatient rehabilitation hospitals across the U.S., generating approximately $5.9 billion in revenue for FY 2025, marking a 10.5% growth, which indicates robust expansion and improved profitability in the post-acute care market.
- Financial Health and Investment Potential: Encompass Health's net income reached nearly $566.2 million with a net margin of 9.5%, and its lower debt-to-equity ratio (around 1.1x) along with free cash flow of approximately $439.2 million provides ample funding for future expansion, showcasing its strong financial health.
See More
